Welcome to our dedicated page for CLOROX CO /DE/ SEC filings (Ticker: CLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CLOROX CO /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CLOROX CO /DE/'s regulatory disclosures and financial reporting.
The Clorox Company reported fiscal 2026 net sales of $6.7 billion, operating in about 25 countries and selling into roughly 95 markets, with over 80% of sales from brands holding No. 1 or No. 2 category positions. Cleaning products contributed 44% of consolidated net sales.
In 2026 Clorox completed the acquisition of GOJO Industries, adding the Purell brand and expanding its health and hygiene and B2B presence, and purchased Procter & Gamble’s 20% interest in the Glad bags and wraps venture. It also finished implementation of a new enterprise resource planning (ERP) system as part of an approximately $580 million multi‑year digital transformation. Net sales declined and diluted EPS fell 26% year over year, primarily due to lower net sales and higher manufacturing and logistics costs.
Clorox ended the year with about 9,200 employees, 77% in the U.S., and a recordable incident rate of 0.63, well below the 2.7 U.S. goods manufacturing average cited. Customer concentration remains high, with Walmart representing 26% of 2026 net sales. The company paid $602 million in dividends and announced a 1% dividend increase for fiscal 2027.
The Clorox Company reported fourth-quarter and fiscal 2026 results marked by lower sales and earnings while integrating its GOJO acquisition and completing a major U.S. ERP transition. Q4 net sales decreased 2% to $1.95 billion, with organic sales down 13% as the company lapped elevated shipments ahead of last year’s ERP cutover. Q4 diluted EPS fell 50% to $1.34 and adjusted EPS declined 42% to $1.66, reflecting lower volume, a 520-basis-point gross-margin decline to 41.3%, and GOJO-related inventory step-up and integration costs.
For fiscal 2026, net sales declined 5% to $6.72 billion and organic sales fell 8%. Diluted EPS decreased 26% to $4.81, while adjusted EPS decreased 28% to $5.53, including an estimated 90-cent headwind from ERP-related shipment timing. Net cash provided by operations was $612 million, down from $981 million, primarily due to the Glad venture-termination payment, while adjusted free cash flow was $881 million. Clorox expects fiscal 2027 net sales to grow 13%–14%, including about 9.5 points from GOJO, and guides diluted EPS to $5.41–$5.71 and adjusted EPS to $5.70–$6.00, aided by lapping the ERP inventory drawdown.
Clorox executive Nina Barton reported a Form 4 reflecting a tax-withholding disposition, where the company withheld 1,681 shares of Common Stock at $95.69 per share to satisfy taxes on vesting of restricted stock. After this, she directly holds 26,443 shares, including 229 acquired via the Stock Incentive Plan’s dividend reinvestment feature. The transaction is not marked as pursuant to a Rule 10b5-1 plan.
Clorox executive Chris T. Hyder, EVP-Chief Operating Officer, reported a tax-related share withholding on 2026-07-15. The company withheld 277 shares of common stock at $94.75 per share to satisfy tax obligations tied to vesting restricted stock, leaving Hyder with 76,860 directly held shares, including 36 acquired through a dividend reinvestment feature.
Clorox director Christopher J. Williams reported two compensation-related awards of deferred stock units. On May 8, 2026, he received 297.0104 deferred stock units, and on June 30, 2026, he received 288.1391 deferred stock units.
The filing explains these units were acquired through dividend reinvestment during the fiscal year and by electing to receive quarterly director fees in deferred stock units under the Independent Directors' Deferred Compensation Plan. Each unit represents a 1-for-1 right to receive Clorox common stock, to be settled in shares after his retirement or other termination of board service. Following the latest award, Williams holds a total of 22,659.7313 deferred stock units directly.
Clorox director Russell J. Weiner reported two compensation-related grants of Deferred Stock Units, increasing his deferred equity-based holdings. He acquired 353.6253 Deferred Stock Units on June 30, 2026 and 242.2414 units on May 8, 2026, both recorded at a price of $0.0000 per unit as non-cash awards.
These units correspond 1-for-1 to shares of Clorox common stock and are linked to the company’s Independent Directors' Deferred Compensation Plan through dividend reinvestment and the election to receive quarterly director fees in Deferred Stock Units. After the June award, Weiner directly holds 18,599.8701 Deferred Stock Units, which will be settled entirely in Clorox stock upon his retirement or other termination of service as a director.
Clorox director Stephanie Plaines reported routine compensation-related awards of deferred stock units, not open-market trades. She acquired 288.1391 deferred stock units on June 30, 2026 and 103.9395 units on May 8, 2026, both at a stated price of $0.
The units were granted under the Independent Directors' Deferred Compensation Plan, including amounts acquired through dividend reinvestment and in lieu of quarterly director fees. After these awards, she held a total of 8,117.1272 deferred stock units, which will be settled entirely in Clorox common stock when she retires from, or otherwise leaves, the board.
Clorox director Pierre R. Breber reported changes in his equity-based compensation and holdings. He indirectly holds 18,000 shares of Clorox common stock through a trust. Separately, he acquired Deferred Stock Units in two transactions: 353.6253 units and 41.7110 units, each representing a right to receive one share of common stock.
The filing notes that these Deferred Stock Units were acquired through dividend reinvestment and in lieu of quarterly director fees under the Independent Directors' Deferred Compensation Plan. The units will be settled entirely in Clorox stock upon his retirement or other termination of service as a director, and he now holds 3,495.4037 Deferred Stock Units directly.
Clorox director Matthew J. Shattock reported two non-cash awards of Deferred Stock Units. He acquired 550.0838 units on June 30, 2026 and 270.7961 units on May 8, 2026, tied to dividend reinvestment and electing fees in stock under the Independent Directors' Deferred Compensation Plan. These units, which track Clorox common stock 1-for-1, will be settled in Clorox shares when he retires or otherwise leaves the board. Following the most recent award, he directly holds 20,947.1472 Deferred Stock Units.
Bellet Luc reported acquisition or exercise transactions in this Form 4 filing.
Clorox Executive Vice President and Chief Financial Officer Luc Bellet received a grant of 42,118 shares in the form of restricted stock units at a reference price of $94.97 per share. These units will vest in full on June 17, 2029, increasing his direct holdings to 62,756 shares.